Amid a series of change-ups to its top executive team this morning, Eli Lilly has moved its biotech buy’s CEO into its oncology division, as Levi Garraway, M.D., Ph.D., hits the exit.
Lilly bought Loxo Oncology for around $8 billion at the start of the year as it looked to boost its cancer work, which has been pretty thin over the years, and eight months down the line is now putting Loxo’s CEO, Josh Bilenker, M.D., in charge of its oncology research and early phase development “in the interim.”
Details are light, but the “interim” part is because this wasn’t a planned succession. Lilly says Garraway has “resigned from his position … in order to pursue other opportunities.”
This comes after a series of setbacks in cancer for the company, including recent safety warnings being slapped on its key breast cancer therapy Verzenio, while also clearing out a host of midstage cancer drugs.
The buying of Loxo was a bright spot for the start of 2019, but just a few short weeks later, it also saw a damaging trial failure for soft tissue sarcoma launch Lartruvo, leading the drugmaker to stop promotion of the drug. With the deal, the company got access to FDA-approved tumor agnostic cancer drug Vitrakvi, which treats patients whose tumors feature a neurotrophic receptor tyrosine kinase gene fusion, regardless of location in the body.
The Loxo deal also brought several pipeline drugs, which Bilenker will be familiar with: a follow-up TRK inhibitor, an oral BTK inhibitor and a RET inhibitor called LOXO-292 that has received an FDA breakthrough therapy designation. LOXO-292 could represent a 2020 launch opportunity, Lilly said.
Bilenker takes over from Garraway, a former associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, but it’s unclear whether this will evolve into a full-time position.
Garraway himself took over three years ago from Richard Gaynor, M.D., who had been at the Big Pharma for 15 years.
By: Ben Adams
Source: Fierce Biotech
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.